The OEM partnership will enable GenapSys customers turn-key access to Twist’s best-in-class target enrichment workflows, providing researchers with optimized assays spanning cancer test panels to whole human exome sequencing
REDWOOD CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#AGBT20–GenapSys Inc., the company behind the world’s first highly accurate, affordable, and portable gene sequencer, today announced a new OEM partnership with Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA. The collaboration will bring a broad and comprehensive range of target enrichment and library preparation tools for next-generation sequencing (NGS) to the GenapSys high accuracy Sequencer offering. Twist’s products will further empower owners of GenapSys’s next-generation sequencer to conduct research in oncology, whole-exome sequencing, rare diseases, viral outbreaks, drug discovery, and more in a simple solution.
The partnership provides significant benefit to customers who will now have the ability to work with a single vendor, cutting down on paperwork and eliminating costly time delays through the convenience of “one stop” shopping. Additionally, research laboratories will have the peace of mind of knowing that the enrichment tools and the gene sequencer will work harmoniously together.
“This OEM collaboration with GenapSys provides an ideal option for research laboratories, government organizations and sequencing providers, including healthcare facilities, to get access to our assays on GenapSys distributed sequencers,” explained Emily M. Leproust, Ph.D., CEO and Co-Founder of Twist Bioscience. “We believe in bringing best-in-class solutions together to offer customers optimal workflows for their needs, and with the distributed nature of the GenapSys high accuracy and affordable sequencer, there is the potential for wider adoption, benefitting a greater number of researchers and clinicians.”
“We’re thrilled to work with an industry leader like Twist Bioscience to give our customers the flexibility and comprehensive capabilities they need from target-enriched, high-quality libraries on our high accuracy sequencing solution, in a single offering,” said Dr. Hesaam Esfandyarpour, Founder and CEO of GenapSys. “Through this partnership, GenapSys enables researchers to have access to an efficient, end-to-end sequencing solution with almost limitless applications in life sciences.”
The collaboration with Twist Bioscience will take effect immediately, with GenapSys integrating the new library preparation and target enrichment products starting in Q2 2020. With the addition of the Twist Bioscience solutions, Genapsys customers will gain access to advanced genomic tools. Researchers will be able to leverage the powerful combination of Twist Bioscience and GenapSys for:
- Tracking of viral outbreaks such as the novel Coronavirus test
- Exome Sequencing for identification of inherited diseases
- Developing tests for cancer detection and monitoring
- Drug discovery and development
- Finding therapies for rare diseases
GenapSys and Twist Bioscience will be attending the Advances in Genome Biology and Technology (AGBT) General Meeting from February 23-26 in Marco Island, Florida. GenapSys will be hosting several presentations from leading genomics researchers as they share their findings and experiences using the GenapSys platform and the outstanding performance data on several applications, including the gold standard accuracy in SNV detection. Presentation topics include; the sequencing of microbes from extreme environments, detection of biologically important – repetitive RNA elements, calling of single nucleotide variants at lower coverage amounts vs comparable technologies, whole exome sequencing, high sensitivity somatic mutation detections in cancer panels, and more.
Interested conference attendees can visit GenapSys at their suite in room Osprey 7, and Twist Bioscience in Caxambus 1, throughout the week, including the four GenapSys’s presentations on Monday and Tuesday, 8:30am, 10:30am in Osprey 7, and posters #209 and #418.
Researchers and clinicians interested in more information on the integration of the Twist Bioscience tools, or parties interested in partnering with GenapSys can contact the company directly via email@example.com.
About GenapSys Inc.
GenapSys is the company behind the world’s first highly accurate direct electronic sequencing technology. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for applications ranging from targeted sequencing of specific amplicons to genome-scale sequencing data collection. The proprietary semiconductor chip-based detection modality allows the system to be compact, scalable, and affordable, empowering the democratization of access to Next-Generation Sequencing, and bringing the power of high-quality genomics into the hands of every researcher or clinician.
Founded by Dr. Hesaam Esfandyarpour, GenapSys’ novel sequencing method is revolutionizing genomics discovery, biomedical research, healthcare, diagnostics, agriculture, and a variety of other fields. GenapSys is headquartered in Redwood City, CA. For more information, visit www.GenapSys.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation the ability of the partnership to eliminate costly time delays, the ability of the enrichment tools and gene sequencer to work harmoniously together, the benefits provided to researchers and clinicians as a result of the partnership and the integration of the new library preparation and target enrichment products starting in Q2 2020, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
GENAPSYS MEDIA CONTACT
VSC for GenapSys
TWIST BIOSCIENCE CONTACTS: